Expression of Insulin-like Growth Factor Family Genes in Clear Cell Renal Cell Carcinoma

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2016 Jul 1

PMID 27358591

Citations 6

Authors

Ryszard Braczkowski

Michal Bialozyt

Marta Plato

Urszula Mazurek

Bogumila Braczkowska

Affiliations

Soon will be listed here.

Abstract

Aim Of The Study: Despite significant progress in the pathology of clear cell renal cell carcinoma (ccRCC), diagnostic and predictive factors of major importance have not been discovered. Some hopes are associated with insulin-like growth factors. The aim of the study was to compare the expression of genes for insulin-like growth factor family in tumours and in tissue of kidneys without cancer.

Material And Methods: Fifty-two patients years with clear cell renal cell cancer were qualified to the study group; patients nephrectomised because of hydronephrosis were included in the control group. Expression of genes were evaluated by RT-PCR.

Results: Expression of IGFR-1 gene in tumour accounts for about 60% of cases. The incidence is higher than in corresponding adjacent non-cancerous kidney tissues and higher (but with no statistical significance) than in kidney without cancer. Expression of IGFR-2 gene in tumours has not been established. The incidence of the expression in corresponding adjacent non-cancerous kidney tissues is small. Expression of this gene has been present in all specimens from kidneys without cancer. Expression of IGFBP-3 gene ascertained in all (except four) cases of ccRCC and in the majority of clippings from adjacent tissue. It was not found in kidneys from the control group. IGF-1, IGF-2, and IGFR-1 mRNA copy numbers in ccRCC were higher than in the material from the control group.

Citing Articles

Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.

Liu Y, Lv H, Li X, Liu J, Chen S, Chen Y Int J Biol Sci. 2021; 17(13):3522-3537.

PMID: 34512163 PMC: 8416721. DOI: 10.7150/ijbs.62114.

IGFLR1 as a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates.

Song W, Shao Y, He X, Gong P, Yang Y, Huang S Front Mol Biosci. 2020; 7:565173.

PMID: 33324675 PMC: 7726438. DOI: 10.3389/fmolb.2020.565173.

Identification of miRNA signatures for kidney renal clear cell carcinoma using the tensor-decomposition method.

Ng K, Taguchi Y Sci Rep. 2020; 10(1):15149.

PMID: 32938959 PMC: 7494921. DOI: 10.1038/s41598-020-71997-6.

The Genes-Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer.

Apanovich N, Peters M, Apanovich P, Mansorunov D, Markova A, Matveev V Diagnostics (Basel). 2020; 10(1).

PMID: 31936274 PMC: 7168144. DOI: 10.3390/diagnostics10010030.

Estrogen affects cell growth and IGF-1 receptor expression in renal cell carcinoma.

Sun L, Gao Z, Luo L, Tan H, Zhang G Onco Targets Ther. 2018; 11:5873-5878.

PMID: 30271170 PMC: 6149902. DOI: 10.2147/OTT.S172149.

References

Hembree J, Harmon C, Nevins T, Eckert R . Regulation of human dermal papilla cell production of insulin-like growth factor binding protein-3 by retinoic acid, glucocorticoids, and insulin-like growth factor-1. J Cell Physiol. 1996; 167(3):556-61. DOI: 10.1002/(SICI)1097-4652(199606)167:3<556::AID-JCP19>3.0.CO;2-1. View

Wang G, Jiang B, Rue E, Semenza G . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92(12):5510-4. PMC: 41725. DOI: 10.1073/pnas.92.12.5510. View

Svensson J, Tivesten A, Sjogren K, Isaksson O, Bergstrom G, Mohan S . Liver-derived IGF-I regulates kidney size, sodium reabsorption, and renal IGF-II expression. J Endocrinol. 2007; 193(3):359-66. DOI: 10.1677/JOE-07-0024. View

Vijayan A, Franklin S, Delmez J, Miller S . Insulin-like growth factor 1 enhances renal function in a patient with chronic renal failure on peritoneal dialysis. Am J Kidney Dis. 2000; 35(1):150-3. DOI: 10.1016/S0272-6386(00)70322-2. View

Schairer C, McCarty C, Isaacs C, Sue L, Pollak M, Berg C . Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Horm Cancer. 2011; 1(2):100-11. PMC: 10358053. DOI: 10.1007/s12672-010-0013-y. View

Rosendahl A, Holly J, Celander M, Forsberg G . Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. Int J Cancer. 2008; 123(6):1286-91. DOI: 10.1002/ijc.23642. View

Zhong H, Agani F, Baccala A, Laughner E, Isaacs W, Simons J . Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998; 58(23):5280-4. View

Yamada T, DE SOUZA A, Finkelstein S, Jirtle R . Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A. 1997; 94(19):10351-5. PMC: 23366. DOI: 10.1073/pnas.94.19.10351. View

Fuhrman S, Lasky L, Limas C . Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6(7):655-63. DOI: 10.1097/00000478-198210000-00007. View

10.

Vatten L, Holly J, Gunnell D, Tretli S . Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2097-100. DOI: 10.1158/1055-9965.EPI-08-0212. View

11.

Orsel J, Sincock P, Krise J, Pfeffer S . Recognition of the 300-kDa mannose 6-phosphate receptor cytoplasmic domain by 47-kDa tail-interacting protein. Proc Natl Acad Sci U S A. 2000; 97(16):9047-51. PMC: 16819. DOI: 10.1073/pnas.160251397. View

12.

Jenkins P, Mukherjee A, Shalet S . Does growth hormone cause cancer?. Clin Endocrinol (Oxf). 2006; 64(2):115-21. DOI: 10.1111/j.1365-2265.2005.02404.x. View

13.

Hintz R, Bock S, Thorsson A, Bovens J, Powell D, Jakse G . Expression of the insulin like growth factor-binding protein 3 (IGFBP-3) gene is increased in human renal carcinomas. J Urol. 1991; 146(4):1160-3. DOI: 10.1016/s0022-5347(17)38031-x. View

14.

Douglas J, Silverman D, Pollak M, Tao Y, Soliman A, Stolzenberg-Solomon R . Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2010; 19(9):2298-306. PMC: 2936681. DOI: 10.1158/1055-9965.EPI-10-0400. View

15.

Volm M, Koomagi R . Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000; 20(3A):1527-33. View

16.

Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A . High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009; 20(5):842-9. DOI: 10.1093/annonc/mdn727. View

17.

Xu Y, Grundy P, Polychronakos C . Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. Oncogene. 1997; 14(9):1041-6. DOI: 10.1038/sj.onc.1200926. View

18.

Yuen J, Cockman M, Sullivan M, Protheroe A, Turner G, Roberts I . The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene. 2007; 26(45):6499-508. DOI: 10.1038/sj.onc.1210474. View

19.

Navai N, Wood C . Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol. 2012; 30(2):220-4. DOI: 10.1016/j.urolonc.2011.10.001. View

20.

Hung R, Moore L, Boffetta P, Feng B, Toro J, Rothman N . Family history and the risk of kidney cancer: a multicenter case-control study in Central Europe. Cancer Epidemiol Biomarkers Prev. 2007; 16(6):1287-90. DOI: 10.1158/1055-9965.EPI-06-0963. View